Section 3(d) — Experimental Data
The examiner asked for proof of enhanced efficacy. That answer comes from a bench.
Section 3(d) of the Patents Act is where a great many Indian pharma and life-science applications die. A new form of a known substance is not patentable unless it differs significantly in properties with regard to efficacy — and 'significantly' means data, not argument. Manna Biotech designs and runs that comparison in its own Hyderabad laboratory and hands your patent agent a technical report they can file.
What's included
Everything you need, nothing you don't.
The comparison, designed properly
A Section 3(d) answer lives or dies on the control. We define the known substance, the new form, the endpoint and the statistics before any bench work starts — because a beautifully executed experiment against the wrong comparator proves nothing.
Antimicrobial efficacy — MIC, MBC, zone
Quantitative antibacterial and antifungal efficacy against defined strains. Numbers, not impressions — the form of evidence an examiner can actually weigh against the known substance.
Microbial identification & characterisation
Where the claim rests on a strain, its identity has to be beyond argument — culture, biochemical characterisation, rRNA sequencing and whole-genome confirmation.
Molecular & expression evidence
RT-PCR gene expression, transcriptomics and AMR genomics, where the enhanced property is mechanistic rather than purely phenotypic.
A report your agent can file
Methods, materials, raw data, statistics and a clear statement of what the data does and does not establish — written to be read by an examiner, not by another scientist.
An honest read before you spend
If we think the comparison is unlikely to show a significant difference, we tell you at the scoping call. A negative result you paid for is a bad week; a negative result you were promised would be positive is a lost application.
Program options
Multiple tracks. One tailored plan for you.
Every Section 3(d) study is scoped individually against the specific objection raised. Tell us your response deadline in the first message — some comparisons cannot be completed inside a short window, and you deserve to know that before you commit.
Scoping call & study design
What has to be proved, against what comparator, by when.
Comparative efficacy study
Bench work against the defined control, with statistics.
Technical report for filing
Examiner-ready methods, data and conclusions.
Supporting characterisation
Identity, purity or mechanism data where the claim needs it.
Fee Structure
Scoped against your objection — quoted before we start.
Send us the objection as the examiner worded it. We will tell you what would have to be shown, whether our laboratory can show it, roughly how long the bench work takes, and what it costs. If the honest answer is that this needs an animal model or a clinical endpoint we do not run, we will say so and point you elsewhere.
- Scoping first — we read the actual objection before quoting
- Deadline-aware — we tell you if it cannot be done in time
- Data belongs to you — raw data supplied with the report
Manna Biotech is not a registered patent agent firm and does not draft, file or prosecute patent applications. We generate scientific and technical evidence, which your registered patent agent files. Our laboratory is not NABL/ISO 17025 accredited; where an accredited report is required, that must be arranged separately.
FAQ
Common questions.
What exactly does Section 3(d) require?+
It says a new form of a known substance is not an invention unless it differs significantly in properties with regard to efficacy. In practice the applicant has to put comparative data on record showing the new form performs meaningfully better than the substance already known. Argument alone does not satisfy it — the examiner is looking for evidence.
Can you guarantee the data will overcome the objection?+
No, and you should not trust anyone who says otherwise. We can guarantee a properly designed comparison, competently executed and honestly reported. Whether that evidence persuades the examiner is a decision for the Patent Office, and whether it is argued well is a matter for your patent agent.
How quickly can you produce data?+
It depends entirely on the assay. Antimicrobial efficacy work can move quickly; sequencing and transcriptomics take longer. Because responses are time-bound under Rule 24B, tell us your deadline up front — we would rather decline than start a study that cannot be finished and reported in time.
Who writes the actual response to the examiner?+
Your registered patent agent. We supply the technical report and are available to explain the science to them, but the response itself, and every legal argument in it, must come from the agent on record. That division is not a preference — it is what the Patents Act requires.
Is this only for pharma?+
No. Section 3(d) bites hardest in pharma, but the same evidence problem appears in nutraceutical, herbal and AYUSH formulations, agri-biotech actives, and probiotic strain claims — anywhere the invention is a new form or combination of something already known.
Get started
Send us the objection. We'll tell you honestly whether data can answer it.
Share a few details and our team will reach out within 24 hours with a tailored plan, syllabus, and fee structure — no obligation.
📍 Nacharam, Hyderabad · 12 min walk from Habsiguda Metro
✉️ admin@mannabiotech.com